Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

HMPL-306 (ranosidenib)

NCT07912398

Hutchmed · Phase 3 · Not yet recruiting · Enrollment 210

NCT07912398

Catalyst Primary completion. 03.2032. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety
HMPL-306 250 mg QDn/r

A count stays a count. This page does not turn a count into a percent.